Abiomed sinks 15% premarket on lowered guidance

Abiomed (ABMD) Q2 results: Revenues: $207.7M (+15.4%).

Impella pump sales: $199.9M (+15.1%).

Net Income: $88.9M (-1.3%); EPS: $1.93 (-1.0%); Non-GAAP EPS: $1.00; CF Ops: $64.6M.

FY 2020 Guidance: Revenue: $885M – 925M from $900M – 945M.

Shares are down 15% premarket.

Previously: Abiomed EPS beats by $0.01, misses on revenue (Aug. 1)

https://seekingalpha.com/news/3485197-abiomed-sinks-15-percent-premarket-lowered-guidance